Video 1 Lumen-apposing metal cyst-gastrostomy stent with visible tissue ingrowth and erosion of the plastic covering.
A 31-year-old woman with a history of alcohol pancreatitis presented with abdominal pain. During her initial admission, she developed an 8.2-cm peripancreatic fluid collection. She underwent successful endoscopic ultrasoundguided drainage of the collection with a 15 mm lumen-apposing metal stent (LAMS). Though instructed to return, the patient was lost to follow-up. She returned to an outside hospital 7 months later with recurrent pancreatitis secondary to alcohol use. Imaging demonstrated resolution of the peripancreatic collection, with the cyst-gastrostomy stent still in situ. The initial attempt at stent removal was unsuccessful. She was then transferred to our institution. During endoscopy the LAMS was seen in the gastric body. Endoscopically, it was evident that the plastic covering had been eroded (▶ Video 1). There was visible tissue ingrowth into the LAMS. The gastric flange was detached from the gastric mucosa using a snare. However, the distal flange was imbedded in the tissue. After multiple attempts, the distal flange was successfully removed using rat tooth forceps after detaching it from tissue. The fistula site had mild oozing after stent removal. Examination of the removed stent demonstrated obvious tissue ingrowth through the degraded plastic covering (▶ Fig. 1 ). After the development of LAMS, endoscopists have created multiple novel anastomoses between various gastrointestinal lumens. Official recommendation from the manufacturing company is to remove these stents 60 days after deployment. However, various studies have demonstrated outcomes beyond 60 days. Examples include pancreatic fluid collections, benign intestinal tract strictures, gallbladder drainage, choledochoduodenostomy [1 -4] . LAMS have remained in place for longer than 2 months, and reportedly have remained patent for greater than 6 months. However, degrading of the plastic coating and tissue ingrowth is a known complication of long-term use of LAMS. Therefore, periodic evaluation of these patients is necessary to ensure timely removal.
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